ASCENDIS PHARMA A/S - ADR (ASND)
US04351P1012 - ADR
| MRQ (2024-9-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 625.51M | 392.16M | 444.80M | 446.30M | 584.50M | |||
| Marketable Securities | 0.00 | 7.28M | 290.70M | 235.80M | 134.30M | |||
| Receivables | 50.35M | 55.77M | 25.60M | 23.20M | 7.30M | |||
| Inventories | 265.43M | 208.93M | 130.70M | 75.40M | N/A | |||
| Other Current Assets | 32.44M | 38.58M | 31.70M | 25.20M | 14.00M | |||
| Total Current Assets | 973.74M | 702.72M | 923.50M | 805.90M | 740.10M | |||
| Non-Current Assets | ||||||||
| PPE Net | 97.52M | 110.63M | 129.10M | 126.00M | 108.10M | |||
| Investments And Advances | 16.21M | 5.69M | 30.40M | 145.90M | 124.50M | |||
| Goodwill | N/A | 3.50M | 3.50M | 3.50M | 3.50M | |||
| Intangibles | 4.11M | 924.00K | 1.30M | 1.80M | 2.20M | |||
| Other Non-Current Assets | N/A | N/A | N/A | N/A | N/A | |||
| Total Non-Current Assets | 120.04M | 122.87M | 166.20M | 279.00M | 239.70M | |||
| TOTAL ASSETS | 1.09B | 825.59M | 1.09B | 1.08B | 979.80M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 422.06M | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 27.67M | 25.40M | 25.40M | 7.00M | 6.90M | |||
| Accounts Payable | 75.27M | 94.57M | 101.00M | 59.40M | 21.90M | |||
| Other Current Liabilities | 313.46M | 77.38M | 44.80M | 33.90M | 24.00M | |||
| Total Current Liabilities | 838.46M | 197.34M | 171.30M | 100.40M | 52.80M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 338.93M | 618.87M | 483.00M | 98.00M | 85.10M | |||
| Deferred Taxes/Income | 8.72M | 5.83M | N/A | N/A | N/A | |||
| Other Non-Current Liabilities | 5.00M | 149.25M | 172.20M | 3.00M | 3.20M | |||
| Total Non-Current Liabilities | 352.65M | 773.94M | 655.10M | 100.90M | 88.30M | |||
| TOTAL LIABILITIES | 1.19B | 971.28M | 826.40M | 201.30M | 141.10M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -2.55B | -2.28B | -1.86B | -1.21B | -897.20M | |||
| Common Shares | 2.45B | 2.13B | 2.12B | 2.12B | 1.74B | |||
| Treasury Stock | -118.00K | -146.00K | -100.00K | -21.60M | N/A | |||
| Other Shareholders' Equity | 953.00K | 721.00K | 3.50M | 3.80M | -100.00K | |||
| Shares Outstanding | 63.04M | 59.99M | 59.46M | 59.15M | 55.92M | |||
| Tangible Book Value per Share | -1.67 | -2.60 | 4.52 | 15.44 | 15.48 | |||
| Total Shareholders' Equity | -97.32M | -145.70M | 263.30M | 883.60M | 838.70M | |||
| TOTAL LIABILITIES AND EQUITY | 1.09B | 825.59M | 1.09B | 1.08B | 979.80M | |||
| Statistics | ||||||||
| Debt/Equity | -7.82 | -4.25 | 1.83 | 0.11 | 0.10 | |||
| Current Ratio | 1.16 | 3.56 | 5.39 | 8.03 | 14.02 | |||
| Return On Assets (ROA) | -38.99% | -58.32% | -53.52% | -35.36% | -42.76% | |||
| Return On Equity (ROE) | N/A | N/A | -221.49% | -43.41% | -49.95% | |||
All data in EUR , ROIC based on taxRate of 0.21